Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34

Adult Aged Antigens, CD34 / metabolism Female Filgrastim / therapeutic use Humans Lymphoma, Non-Hodgkin / drug therapy Male Middle Aged Polyethylene Glycols / therapeutic use Prospective Studies

Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 06 2018
revised: 01 09 2018
accepted: 05 09 2018
pubmed: 20 11 2018
medline: 7 5 2019
entrez: 20 11 2018
Statut: ppublish

Résumé

Data are limited on the long-acting granulocyte-colony stimulating factors (G-CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding the mobilization efficiency of CD34 In this prospective nonrandomized study, 36 patients with non-Hodgkin lymphoma received FIL, 67 received PEG, and 16 patients received LIPEG as a cytokine after chemotherapy. We analyzed the mobilization and collection of CD34 Patients in the LIPEG group had fewer apheresis sessions (1 vs. 2, p = 0.021 for FIL and p = 0.111 for PEG) as well as higher median blood CD34 LIPEG appears to be more efficient compared with PEG after chemotherapy to mobilize CD34

Sections du résumé

BACKGROUND
Data are limited on the long-acting granulocyte-colony stimulating factors (G-CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding the mobilization efficiency of CD34
STUDY DESIGN AND METHODS
In this prospective nonrandomized study, 36 patients with non-Hodgkin lymphoma received FIL, 67 received PEG, and 16 patients received LIPEG as a cytokine after chemotherapy. We analyzed the mobilization and collection of CD34
RESULTS
Patients in the LIPEG group had fewer apheresis sessions (1 vs. 2, p = 0.021 for FIL and p = 0.111 for PEG) as well as higher median blood CD34
CONCLUSION
LIPEG appears to be more efficient compared with PEG after chemotherapy to mobilize CD34

Identifiants

DOI: 10.1111/trf.14993 PMID: 30450652
pubmed: 30450652
doi: 10.1111/trf.14993
doi:

Substances chimiques

Antigens, CD34 0
pegfilgrastim 3A58010674
Polyethylene Glycols 3WJQ0SDW1A
Filgrastim PVI5M0M1GW

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-334

Informations de copyright

© 2018 AABB.

Auteurs

A Partanen (A)

Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Department of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

J Valtola (J)

Department of Medicine, Kuopio University Hospital, Kuopio, Finland.

A Ropponen (A)

Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.

H Kuitunen (H)

Department of Oncology, Oulu University Hospital, Oulu, Finland.

O Kuittinen (O)

Department of Oncology, Oulu University Hospital, Oulu, Finland.

K Vasala (K)

Department of Oncology, Central Hospital of Central Finland, Jyväskylä, Finland.

L Ågren (L)

Siunsote- Hospital District of North Karelia, Joensuu, Finland.

K Penttilä (K)

Department of Medicine, Central Hospital of Savonlinna, Savonlinna, Finland.
The Finnish Medicines Agency, Kuopio, Finland.

L Keskinen (L)

Department of Oncology, Tampere University Hospital, Tampere, Finland.

M Pyörälä (M)

Department of Medicine, Kuopio University Hospital, Kuopio, Finland.

T Nousiainen (T)

Department of Medicine, Kuopio University Hospital, Kuopio, Finland.

T Selander (T)

Science Service Center, Kuopio University Hospital, Kuopio, Finland.

P Mäntymaa (P)

Eastern Finland Laboratory Centre, Kuopio, Finland.

J Pelkonen (J)

Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland.
Eastern Finland Laboratory Centre, Kuopio, Finland.

V Varmavuo (V)

Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.

E Jantunen (E)

Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
Siunsote- Hospital District of North Karelia, Joensuu, Finland.
Department of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes CD › Antigènes CD34 › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Facteur de stimulation des colonies de granulocytes › Filgrastim › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Comparison of filgrastim, pegfilgrastim, and...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Comparison of filgrastim, pegfilgrastim, and...